Replies to post #705310 on NorthWest Biotherapeutics Inc (NWBO)

[Margin Buu]

jon_k84 made a fine sum up of your scam:

DC-VAX is not real, it's a scam company.
-Ok, it's a real company, but DC-Vax doesn't work.
-OK, DC-Vax might work, but the trial is badly designed and statistical analysis plan will never get accepted.
-OK, SAP got accepted, but they'll never release top line data.
-OK, they'll release top line data, but a journal will never publish it.
-OK, a journal might publish it, but not top-tier.
-OK, a top-tier journal published it, but some major doctors dissented and they will never get a regulatory application out.
-OK, they got the regulatory application out, but it won't be accepted.
-OK, the regulatory application to the MHRA was accepted, but it'll never get approved.

Add to that the best state of the art dendritic cells automation and scaling device on the market, enabling lowering of cost and quick manufactoring of doses. Patented IP globally. One 14 year long combo trial with results published in Nature and one with Keytruda at UCLA nearing its primary completion date. And a british report two years in the making, regarding Britains efforts on glioblastoma including top priority of getting MHRA to approve and NICE to reimburse DCVax-L.

What’s next on the list?

-OK, the MHRA approved the regulatory application for DCVax-L, but… oh shit! (queue the FUDster rats bailing from their capsized ship)

[Zadie420]

With all due respect, I have enjoyed reading your post and is informative I like to know which part of the post by OB was false. When you are trading in OTC land you should expect the PPS gets knock down when you issue more shares to the market. This applies to all stocks in OTC since there is no official oversight.

You gotta be careful with your spending when you are trading in OTC, Unless you come up with alternative finances to put the stop on issuing more shares to the market.

[learningcurve2020]

>>The plan to align management and shareholder interests by awarding executives stock options not only was oversold, but also subtly disguised a deeper division between those interests that the options created. Many corporations pay their managers stock options whose value increases simply by retention of earnings, rather than by superior deployment of capital. As Buffett explains, however, simply by retaining and reinvesting earnings, managers can report annual earnings increases without so much as lifting a finger to improve real returns on capital. Stock options thus often rob shareholders of wealth and allocate the booty to executives. Moreover, once granted, stock options are often irrevocable, unconditional, and benefit managers without regard to individual performance.

It is possible to use stock options to instill a managerial culture that encourages owner-like thinking, Buffett agrees. But the alignment will not be perfect. Shareholders are exposed to the downside risks of sub-optimal capital deployment in a way that an option holder is not. Buffett therefore cautions shareholders who are reading proxy statements about approving option plans to be aware of the asymmetry in this kind of alignment. Many shareholders rationally ignore proxy statements, but the abuse of stock options should be on the front-burner of shareholders, particularly institutional investors that periodically engage in promoting corporate governance improvements.

Buffett emphasizes that performance should be the basis for executive pay decisions. Executive performance should be measured by profitability, after profits are reduced by a charge for the capital employed in the relevant business or earnings retained by it. If stock options are used, they should be related to individual performance, rather than corporate performance, and priced based on business value. Better yet, as at Berkshire, stock options should simply not be part of an executive’s compensation. After all, exceptional managers who earn cash bonuses based on the performance of their own business can simply buy stock if they want to; if they do, they “truly walk in the shoes of owners,” Buffett says. And owners’ interests are paramount on executive pay as with other corporate governance topics Buffett addresses, such as risk management, corporate compliance and financial reporting.

-Buffet

[learningcurve2020]

That's one crazy rant, DanishDancer. I don't think Buffet is talking about averaging down. LOL


>>Warren Buffett once said, “The first rule of an investment is don't lose [money]. And the second rule of an investment is don't forget the first rule. And that's all the rules there are.”Apr 18, 2024

[Legend431]

You are not an investor Danish dud. You are all in on an otc stock. You just tout one stock. An investor invests in many securities and companies like Michael bigger and the likes of other capital groups. You are just all in hoping for one home run.

[iclight]

Nice wall of bullshit. As I've said before I've actually made money on this. A little less than what you've lost.

Simple trading with LPs pump and dump scheme back in 2014-16.